Skip to main content

February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology

Ayvakit First Targeted Therapy Approved for Gastrointestinal Stromal Tumors with PDGFRA Mutation

Breast Cancer, FDA Approvals, Oncology

Enhertu, a Dual-Targeted Therapy, Approved for Metastatic HER2-Positive Breast Cancer

Padcev, a Novel Targeted Therapy, FDA Approved for Advanced or Metastatic Urothelial Cancer

Tazverik First FDA-Approved Drug for Advanced Epithelioid Sarcoma Ineligible for Resection

Leukemia, Oncology, Practice Management

First National Study: Geographic Socioeconomic Disparities Mirror Substantial Gaps in Survival in Children with AML

Chase Doyle

FDA Approvals, Pancreatic Cancer, Oncology

Lynparza Indicated for Maintenance Treatment of Metastatic Pancreatic Cancer with BRCA Mutation

Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy

Phoebe Starr

In the Literature, Oncology

Luspatercept Effective in Patients with Lower-Risk Myelodysplastic Syndromes

Conference Highlights ASH

Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019

Wayne Kuznar

In the Literature, Oncology

Split-Fill Program for Oncology Oral Medications Is Cost-Saving

Page 2 of 3
Results 11 - 20 of 26